company background image
MYNZ

Mainz Biomed B.V NasdaqCM:MYNZ Stock Report

Last Price

US$9.24

Market Cap

US$129.0m

7D

-1.9%

1Y

n/a

Updated

15 Aug, 2022

Data

Company Financials +
MYNZ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MYNZ Stock Overview

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.

Mainz Biomed B.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mainz Biomed B.V
Historical stock prices
Current Share PriceUS$9.24
52 Week HighUS$30.00
52 Week LowUS$7.80
Beta0
1 Month Change-1.70%
3 Month Change-22.42%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-7.51%

Recent News & Updates

Shareholder Returns

MYNZUS BiotechsUS Market
7D-1.9%1.4%3.6%
1Yn/a-19.6%-9.6%

Return vs Industry: Insufficient data to determine how MYNZ performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MYNZ performed against the US Market.

Price Volatility

Is MYNZ's price volatile compared to industry and market?
MYNZ volatility
MYNZ Average Weekly Movement11.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: MYNZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MYNZ's weekly volatility has decreased from 18% to 11% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008n/aGuido Baechlerhttps://mainzbiomed.com

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed B.V. Fundamentals Summary

How do Mainz Biomed B.V's earnings and revenue compare to its market cap?
MYNZ fundamental statistics
Market CapUS$128.99m
Earnings (TTM)-US$11.69m
Revenue (TTM)US$577.35k

223.5x

P/S Ratio

-11.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MYNZ income statement (TTM)
RevenueUS$577.35k
Cost of RevenueUS$399.73k
Gross ProfitUS$177.62k
Other ExpensesUS$11.87m
Earnings-US$11.69m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.84
Gross Margin30.76%
Net Profit Margin-2,024.79%
Debt/Equity Ratio33.5%

How did MYNZ perform over the long term?

See historical performance and comparison